SC
FLGT icon

Scholtz & Company’s Fulgent Genetics FLGT Stock Holding History

Scholtz & Company’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-186,750
Closed -$895K – 63
2017
Q3 		$895K Sell
186,750
-63,830
-25% -$367K 0.7% 41
2017
Q2 		$1.6M Sell
250,580
-16,125
-6% -$130K 1.38% 35
2017
Q1 		$2.91M Buy
266,705
+89,205
+50% +$1.05M 2.47% 17
2016
Q4 		$2.05M Buy
+177,500
New +$1.68M 1.78% 28

Other funds holding FLGT

MA
Mutual Advisors Omaha, Nebraska $5.31B AUM 25.12% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Scholtz & Company's FLGT Position: Q4 2017 in Review

Scholtz & Company sold out of Fulgent Genetics (FLGT) in Q4 2017, closing a stake of 186,750 shares — an estimated $895K sold.

Scholtz & Company first reported a position in FLGT in Q4 2016 and held it in 4 quarters. The position peaked at $2.91M in Q1 2017. 18 funds tracked by Wall St. Rank hold FLGT as of Q4 2017.

  • Scholtz & Company reported no remaining Fulgent Genetics position as of Q4 2017 after selling out during the quarter.
  • Scholtz & Company sold 186,750 Fulgent Genetics shares in Q4 2017, an estimated $895K.
  • Scholtz & Company first reported a position in Fulgent Genetics in Q4 2016 and held it in 4 quarters.
  • Scholtz & Company's Fulgent Genetics position peaked at $2.91M in Q1 2017.
  • 18 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2017.

Based on Scholtz & Company's 13F filing for Q4 2017, filed 14 Feb 2018.